Skip to content
OpenCapital
Get started

Alnylam Pharmaceuticals ALNY Q4 2025 Annual earnings

Reported February 12, 2026 · Before market open

Revenue$1.1BMiss by $52.1MDiluted EPS$0.82Miss by $0.34
Revenue estimate$1.1B
EPS estimate$1.16

Next report

Jul 30, 2026 (In 2 weeks)
Revenue estimate$1.3B
EPS estimate$1.61

Financials

Q4 2025

Income statement

See full
Revenue$1.1B+84.9%
Gross profit$829.3M+69.1%
Operating income$131.7M+225%
Net income$111.5M+233%
EPS (diluted)$0.82+226%

Balance sheet

See full
Cash & equivalents$1.7B+71.2%
Total debt$270.6M-0.3%
Total equity$789.2M+1,076%
Total assets$5.0B+17.1%

Cash flow

See full
Operating cash flow$163.6M+273%
CapEx$23.3M+156%
Free cash flow$140.3M+235%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$52.54B+73.1%
Enterprise value$51.15B+72.5%
P/E188.9×—
P/S14.1×+0.6×

Profitability

See full
Gross margin81.8%-4.6pp
Operating margin13.5%+9.9pp
Net margin7.5%+4.6pp
FCF margin12.5%+11.1pp

Returns & leverage

See full
Return on equity65%—
Debt / equity0.3×-3.7×
Current ratio2.8×0.0×

Versus estimates

Revenue

Q1 2026$1.2BBeat by $51.7M
Q4 2025$1.1BMiss by $52.1M
Q3 2025$1.2BBeat by $289.6MQ2 2025$773.7MBeat by $110.8MQ1 2025$594.2MBeat by $9.0MQ4 2024$593.2MBeat by $10.6M

Diluted EPS

Q1 2026$1.51Beat by $0.64
Q4 2025$0.82Miss by $0.34
Q3 2025$2.90Beat by $2.34Q2 2025$0.32Beat by $0.86Q1 2025-$0.01Beat by $0.88Q4 2024$0.06Beat by $0.68

Ask the moment Alnylam Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Alnylam Pharmaceuticals report Q4 2025 earnings?
Alnylam Pharmaceuticals (ALNY) reported Q4 2025 earnings on February 12, 2026 before market open.
What were Alnylam Pharmaceuticals's Q4 2025 revenue and EPS?
Alnylam Pharmaceuticals reported revenue of $1.1B and diluted EPS of $0.82 for Q4 2025.
Did Alnylam Pharmaceuticals beat estimates in Q4 2025?
Revenue missed the consensus estimate of $1.1B by $52.1M. EPS missed the consensus estimate of $1.16 by $0.34.
How did Alnylam Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 84.9% from $593.2M a year earlier and diluted EPS grew 1266.7% from $0.06.
Where can I find Alnylam Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-007491) and the 10-K periodic report (0001628280-26-007497) directly on SEC EDGAR. The filing index links above go to sec.gov.